Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Frequently asked questions
What sector does Avadel Pharmaceuticals plc (AVDL) operate in?
Avadel Pharmaceuticals plc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Avadel Pharmaceuticals plc (AVDL) current stock price?
As of the latest data, Avadel Pharmaceuticals plc stock price is $21.64, with a previous close of $21.64.
What is Avadel Pharmaceuticals plc (AVDL) current market capitalization?
Avadel Pharmaceuticals plc market cap is approximately 2.12 billion.
Does Avadel Pharmaceuticals plc (AVDL) pay dividends?
No. Avadel Pharmaceuticals plc does not pay a dividend.
What is Avadel Pharmaceuticals plc (AVDL) beta (volatility) score?
Avadel Pharmaceuticals plc has a beta of 1.632, suggesting it is more volatile than the market.
